Loading article…
Danaher shares trade near the low end of historical multiples after a $9.9 bn Masimo acquisition and a $125 m cost‑savings target, signaling a potential
Danaher (DHR) shares are hovering at the low end of their long‑term valuation range, with analysts pointing to a $9.9 billion Masimo acquisition and a $125 million cost‑savings target as catalysts for earnings acceleration【3】.
| At a glance | |
|---|---|
| Acquisition size | $9.9 bn (Masimo) |
| Cost‑savings target | $125 m |
| EPS accretion estimate | 15‑20 c per share |
| Valuation | Near low end of historical multiples |
Danaher’s recent purchase of pulse‑oximetry leader Masimo for $9.9 billion expands its high‑margin medical‑device portfolio. The deal is expected to be “roughly 15 to 20 cents accretive to adjusted earnings per share in the first full year post‑close,” according to CFO Matthew Gugino during the April earnings call【3】. Management also aims to generate $125 million in cost reductions by applying the Danaher Business System (DBS) to Masimo’s operations, a figure described as “almost certainly conservative” given the scale of the target company’s inefficiencies【3】.
Danaher’s core life‑sciences segment is emerging from a two‑year post‑pandemic destocking slump, which should lift recurring revenue and improve margins. Combined with the anticipated Masimo margin improvements, analysts see a re‑acceleration of earnings growth. Despite these fundamentals, the stock remains priced at the lower end of its historical multiple range, suggesting the market is still valuing the company on a “depressed, cyclical‑trough earnings” basis【3】. This valuation gap positions Danaher as a “world‑class asset currently on sale,” according to the CNBC commentary.
The juxtaposition of a low valuation with tangible acquisition synergies and cost‑cutting targets makes Danaher a focal point for investors seeking exposure to a “master contractor” model in healthcare, while the upcoming earnings report will test whether the anticipated upside materializes.
Coverage is mostly measured — 116 of 138 reports stay neutral.
Every Monday — the token unlocks, Fed dates & catalysts set to move crypto and markets this week. So you’re never blindsided.
Free · 3-min read · one-click unsubscribe
AI-assisted synthesis by the TrendWatcher Editorial Desk · sourced from 3 outlets · Jul 17, 2026 · How we report
FactSet data shows that 87% of the roughly 40 S&P 500 companies that have reported so far have exceeded analyst expectations.
Alphabet, Tesla, and Intel are among the headline names slated to release earnings in the upcoming week.
S&P 500 futures rose after June consumer price data showed the biggest decline in over six years, indicating a temporary relief from persistent inflation.
Analysts have upgraded Deckers Outdoors to buy, raised Intel’s price target to $155, and increased UnitedHealth’s target to $475, reflecting confidence in their earnings prospects.
Morgan Stanley suggests a diversified income model that includes international assets, master limited partnerships, REITs, commodities, and a focus on quality dividend earners, AI beneficiaries, and fiscal policy winners.